<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141969</url>
  </required_header>
  <id_info>
    <org_study_id>RLP10242019</org_study_id>
    <nct_id>NCT04141969</nct_id>
  </id_info>
  <brief_title>A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome</brief_title>
  <acronym>PLDS</acronym>
  <official_title>A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of a nutraceutical in treating the lingering
      effects of Lyme Disease after antibiotic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome will be evaluated during a double
      blind, placebo controlled study. This study is an expansion of RLP042019 NCT04078841 Treating
      Post-Lyme Disease Syndrome With Acetogenins
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">April 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PROMIS Global-10</measure>
    <time_frame>6 months</time_frame>
    <description>PROMIS Global-10; Self reported level changes as measured by the Patient-Reported Outcomes Measurement Information System Global-10 .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IHT Blood Test Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Outcome measure of &quot;positive&quot; or &quot;negative&quot; for antibodies; IgG P93 Ab. IgG P66 Ab. IgG P58 Ab. IgG P45 Ab. IgG P41 Ab. IgG P39 Ab. IgG P30 Ab. IgG P28 Ab. IgG P23 Ab. IgG P18 Ab.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Post-Lyme Disease Syndrome (PLDS)</condition>
  <arm_group>
    <arm_group_label>RLP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ReaLife+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inert</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert brown powder to look similar to RLP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not given RLP or the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RLP</intervention_name>
    <description>RLP nutraceutical</description>
    <arm_group_label>RLP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inert brown powder</description>
    <arm_group_label>Inert</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A positive two-test methodology using a sensitive enzyme immunoassay (EIA) or
             immunofluorescence assay as a first test, followed by a western immunoblot assay for
             specimens yielding positive or equivocal results for Lyme Disease that has been
             treated with antibiotics but the symptoms persist post treatment.

          2. Must be able to swallow a mixed powder drink.

        Exclusion Criteria:

        1 .Non Positive Western Blot test.

        2. Positive Western Blot test where the individual has not been treated with antibiotics.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Osguthorpe, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Health Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lyme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Post-Lyme Disease Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

